Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02117739 · ClinicalTrials.gov registry record · Phase 1

Photoallergy Potential of Dapsone Gel in Healthy Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by Almirall, S.A..

Completed
Registry status
Phase 1
Development phase
58
Enrollment target
1
Study location

NCT02117739: Completed Phase 1 study of Healthy Volunteers, sponsored by Almirall, S.A..

NCT02117739 is a Phase 1 study of Healthy Volunteers that has completed, run by Almirall, S.A.. The registered enrollment target is 58 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02117739, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Almirall, S.A..

COMPLETED
Registry status
Phase 1
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the potential of dapsone gel and its vehicle to cause a photoallergic reaction after repeated application and irradiation to the skin of healthy volunteers under controlled conditions.

Conditions Studied

Interventions

  • DRUG dapsone gel
  • DRUG dapsone gel vehicle

Study Locations (1)

New Jersey

  • - Fair Lawn

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2014-04
Est. Completion 2014-07
Phase Phase 1
Almirall, S.A.

19 total trials

What the finished NCT02117739 record still lists

NCT02117739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which dapsone gel is the first listed.

NCT02117739 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT02117739 about?

NCT02117739 is a clinical study titled "Photoallergy Potential of Dapsone Gel in Healthy Volunteers". This study will evaluate the potential of dapsone gel and its vehicle to cause a photoallergic reaction after repeated application and irradiation to the skin of healthy volunteers under controlled conditions.

What is the current status of trial NCT02117739?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2014-04. Estimated completion is 2014-07.

What conditions does trial NCT02117739 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02117739?

The interventions under investigation include: dapsone gel (DRUG), dapsone gel vehicle (DRUG).

Who is sponsoring clinical trial NCT02117739?

This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02117739 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02117739's enrollment target sits among peer trials

58 124th of 283 higher than 158 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02117739, the US trial registry maintained by the National Library of Medicine. NCT02117739 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.